vaginal candidiasis. Candidiasis of vulva and vagina
Conditions
Interventions
Intervention 1: First intervention group :Take one dose of 150 mg fluconazole tablets and then a daily 500 mg probiotic placebo capsule (containing starch and made by the researcher) for one month. Da
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 49 Years
Inclusion criteria
Inclusion criteria: Married women aged 15-49 (lack of virginity) Positive culture of discharge from the candidate's point of view Be literate Willingness to participate in the study and the possibility of visiting the clinic at the requested times Having a contact phone Living in the city of Tabriz
Exclusion criteria
Exclusion criteria: Pregnancy, lactation and menopause Use of antibiotics and immunosuppressive drugs (corticosteroids, etc.) and use of vaginal drugs during the last two weeks Currently taking oral contraceptives according to the participant Having autoimmune diseases Having chronic diseases such as diabetes, anemia, hypothyroidism, etc. Having menstrual bleeding during the visit of the participant Abnormal uterine bleeding Non-candidal vaginitis Recurrent vulvovaginitis (four or more cases during the year) Symptoms of drug allergy Consumption of any probiotic product (supplements, food, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of negative culture in two intervention groups. Timepoint: Day 40-35 after starting treatment and day 65-60 after starting treatment. Method of measurement: Cultivation in the laboratory. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patients complain of foul-smelling discharge. Timepoint: Day 35-40 and day 60-65 after starting treatment. Method of measurement: Questionnaire of signs and symptoms of the person.;Patients complain of itching. Timepoint: Day 35-40 and day 60-65 after starting treatment. Method of measurement: Questionnaire of signs and symptoms of the person.;Patients complain of burning. Timepoint: Day 35-40 and day 60-65 after starting treatment. Method of measurement: Questionnaire of signs and symptoms of the person.;Patients complain of inflammation and vaginal erythema. Timepoint: Day 35-40 and day 60-65 after starting treatment. Method of measurement: Questionnaire of signs and symptoms of the person.;Patients complain of frequent urination. Timepoint: Day 35-40 and day 60-65 after starting treatment. Method of measurement: Questionnaire of signs and symptoms of the person.;Patients complain of urinary incontinence. Timepoint: Day 35-40 and day 60-65 after starting treatment. Method of measurement: Questionnaire of signs and symptoms of the person.;Patients complain of pain during intercourse. Timepoint: Day 35-40 and day 60-65 after starting treatment. Method of measurement: Questionnaire of signs and symptoms of the person.;Vaginal pH. Timepoint: Day 35-40 and day 60-65 after starting treatment. Method of measurement: Checklist for recording observations and clinical results.;Satisfaction rate. Timepoint: Day 35-40 after starting treatment. Method of measurement: Personal Satisfaction Questionnaire.;Adverse events during the intervention. Timepoint: Any time of study. Method of measurement: Checklist for side effects. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Mollazadeh Narestan
Tabriz University of Medical Sciences
Outcome results
None listed